logo

For the Inventor, By the Inventor

Macclesfield, United Kingdom

Andrew Stocker

This inventor holds 17 USPTO granted patents and 1 published patent application, primarily in Heterocyclic Compounds. Top assignees: Astrazeneca Ab, Zeneca Limited, Astra Zeneca U.k. Limited. Active years: 1999-2013.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andrew Stocker. Retrieved from https://idiyas.com/inventor/andrew-stocker

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 17 

% Patents Active = 35.3

Average Co-Inventor Count = 3.4

ph-index = 3

Forward Citations = 140(Granted Patents)


Location History:

  • MacClesfield, GB (1999 - 2011)
  • Cheshire, GB (2006 - 2013)

Company Filing History:

goldMedal10 out of 1,534 
 
Astrazeneca Ab
 patents
silverMedal6 out of 854 
 
Zeneca Limited
 patents
bronzeMedal1 out of 110 
 
Astra Zeneca U.k. Limited
 patents

Years Active: 1999-2013

Loading Chart...
Areas of Expertise:
Heterocyclic Compounds
Glycogen Phosphorylase
Factor Xa Inhibitors
Aminoheterocyclic Derivatives
Thienopyrrole Derivatives
Indole-Amid Derivatives
Antithrombotic Agents
Chemical Compounds
Pyrazole Derivatives
Crystalline Forms
Intermediates Preparation
Heteroaryl-Sulfonamide
17 patents (USPTO):Explore Patents
1. 8344016 - Pyrazole derivatives as 11-beta-HSD1 inhibitors (2013-01-01),
2. 7951833 - Crystalline forms of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]Benzoic acid 471 (2011-05-31),
3. 7816391 - Chemical compounds (2010-10-19),
4. 7411074 - Process and intermediates for the preparation of the thienopyrrole derivatives (2008-08-12),
5. 7332515 - Indole-amid derivatives which possess glycogen phosphorylase inhibitory activity (2008-02-19),
6. 7307174 - Process and intermediates for the preparation of thienopyrrole derivatives (2007-12-11),
7. 7276517 - Heterocyclic amide derivatives as inhibitors of glycogen phosphorylase (2007-10-02),
8. 7173025 - Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents (2007-02-06),
9. 7166636 - Indole-amid derivatives which possess glycogen phosphorylase inhibitory activity (2007-01-23),
10. 7129249 - Heterocyclic amide derivatives as inhibitors of glycogen phoshorylase (2006-10-31),
11. 6936610 - Heterocyclic derivatives (2005-08-30),
12. 6730672 - Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents (2004-05-04),
13. 6486154 - (Hetero) aryl-sulfonamide derivatives, their preparation and their use as factor XA inhibitors (2002-11-26),
14. 6395731 - Heterocyclic derivatives which inhibit Factor Xa (2002-05-28),
15. 6300330 - Heterocycle derivatives which inhibit factor Xa (2001-10-09),

Title: The Innovative Contributions of Andrew Stocker

Introduction

Andrew Stocker is a notable inventor based in Macclesfield, GB. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit 11-beta-HSD1. With a total of 17 patents to his name, Stocker has established himself as a key figure in innovation.

Latest Patents

Among his latest patents are the pyrazole derivatives as 11-beta-HSD1 inhibitors. This patent describes a compound of formula (I) and pharmaceutically-acceptable salts thereof, wherein the variable groups are defined within. The patent also details their use in the inhibition of 11-beta-HSD1, processes for making them, and pharmaceutical compositions comprising them. Another significant patent involves new crystalline forms of 4-[4-(2-adamantylcarbamoyl)-5-tert-butyl-pyrazol-1-yl]benzoic acid. This patent outlines their use in the inhibition of 11-beta-HSD1, processes for making them, and pharmaceutical compositions comprising them.

Career Highlights

Stocker has worked with prominent companies in the pharmaceutical industry, including AstraZeneca AB and Zeneca Limited. His work in these organizations has contributed to advancements in drug development and innovation.

Collaborations

Throughout his career, Stocker has collaborated with notable colleagues such as John Preston and Paul Robert Owen Whittamore. These collaborations have likely enhanced his research and development efforts.

Conclusion

Andrew Stocker’s contributions to the field of pharmaceuticals through his innovative patents and collaborations highlight his importance as an inventor. His work continues to influence the development of new therapeutic compounds.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…